共 50 条
- [1] Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Abdul-Karim, Raghad MuhsinTolcher, Anthony W.Kummar, ShivaaniPatel, Manish R.Spira, Alexander I.Jauhari, ShekeabDuff, MaureenXu, RongdaJohnson, AnnDaemen, AnneleenMultani, Pratik S.Maneval, Edna ChowMunster, Pamela N.
- [2] ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsCANCER RESEARCH COMMUNICATIONS, 2024, 4 (09): : 2415 - 2426Chen, Christopher T.Khanna, VisheshKummar, ShivaaniAbdul-Karim, Raghad M.Sommerhalder, DavidTolcher, Anthony W.Ueno, Naoto T.Davis, Sarah LindseyOrr, Douglas W.Hamilton, ErikaPatel, Manish R.Spira, Alexander I.Jauhari, ShekeabFlorou, VaiaDuff, MaureenXu, RongdaWang, JianBarkund, Shravani R.Zhou, HaiyingPankov, AleksandrKong, WayneJahchan, Nadine S.Jackson, Erica L.Sun, Jessica D.Junttila, Melissa R.Multani, Pratik S.Daemen, AnneleenManeval, Edna ChowMunster, Pamela N.
- [3] Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamideMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Daemen, AnneleenBarkund, ShravaniJohnson, AnnPankov, AleksandrWang, Amber W.Zhou, HaiyingMultani, Pratik S.Maneval, Edna ChowFriedman, Lori S.Patel, Rupal
- [4] Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancerMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Abida, WassimAgarwal, NeerajHahn, Andrew W.Shore, NealSieber, PaulDorff, TanyaRettig, MathewSmith, MathewMonk, PaulXu, RongdaJohnson, AnnDaemen, AnneleenManeval, Edna ChowMultani, Pratik S.Patel, RupalMorris, Michael J.
- [5] A phase 1b study of ruxolitinib (Rux) plus gemcitabine (G) ± nab-paclitaxel (N) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Bauer, Todd MichaelPatel, Manish R.Wood, Tina EvansGeorge, Thomas J.Dawkins, Fitzroy W.Brill, Kimberli J.Du, YiningHurwitz, Herbert
- [6] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyCLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526Johnson, MelissaDudek, Arkadiusz Z.Sukari, AmmarCall, JustinKunk, Paul R.Lewis, KarlGainor, Justin F.Sarantopoulos, JohnLee, PatriceGolden, AdeleHarney, AllisonRothenberg, S. MichaelZhang, YuanyuanGoldman, Jonathan W.
- [7] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumorsCANCER RESEARCH, 2017, 77Bendell, JohannaFuchs, CharlesVoss, MartinBauer, Todd M.Choueiri, Toni K.Drilon, AlexanderThorn, KatharineWijayawardana, SameeraMoser, BrianUrunuela, ArantxaWacheck, VolkerHarding, James J.
- [8] A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Juric, DejanFaucette, StephanieWang, LingNiu, HuifengKannan, KaruppiahStump, KateRong, YuanxinShou, YapingNemunaitis, John J.
- [9] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Dasari, ArvindKauh, John S.Tucci, ChristopherNanda, ShivaniKania, Marek K.Carlisle, Jennifer W.Paulson, Andrew Scott
- [10] A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studyCancer Chemotherapy and Pharmacology, 2016, 77 : 693 - 701Steven J. CohenBert H. O’NeilJordan BerlinPatricia AmesMarti McKinleyJulie HoranPatricia M. CatalanoAngela DaviesColin D. WeekesLawrence Leichman